RUNX3 and brain neoplasm: The results of the MS‐HRM analysis of all analyzed genes (SFRP1, SFRP2, RUNX3, CBLN4, INA, MGMT, and RASSF1A) showed that their promoter sequence methylation level is significantly higher (P < 0.0001) in DNA samples from brain tumor patients than in the non‐neoplastic brain sample (Figure 1).